New drug cocktail aims to tackle resistant lung cancer

NCT ID NCT07193160

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a combination of two drugs—sacituzumab tirumotecan and furmonertinib—in 45 people with advanced EGFR-mutant non-small cell lung cancer whose first targeted therapy stopped working. The study measures how many patients respond to treatment and how long the benefit lasts. It is a single-arm, open-label trial, meaning everyone gets the same treatment and there is no placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab tirumotecan (a drug that targets cancer cells) and furmonertinib (a targeted therapy pill)
What this could lead to: If this combination works, it could offer a new second-line treatment option for people with a specific type of advanced lung cancer whose first treatment stopped working.
What could go wrong: This is a small, early-phase (Phase II) trial with only 45 people and no comparison group, so results may not apply broadly. The drug combination may cause side effects or not improve outcomes significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (NON-SMALL CELL LUNG CANCER)

More trials for these conditions

Other studies related to the condition(s) this trial covers.